Modelling Intestinal Toxicity
Using Organoids

Calling all organoid researchers! 

In this webinar, Dr. Valentina Ubertini explores Epistem's intestinal organoids as powerful tools in drug discovery. Utilising the Hans Clevers method, our team has developed intestinal organoid models to assess potential off-target toxicities of new therapeutic agents.

Date: February 15th 2024      Time: 1pm - 2pm GMT

Register Now ➤
To the main site
Contact us

Organoids

Models derived from stem cells and generate differentiated lineages.

Organoids have an innate ability to self-assemble into three-dimensional formations that closely reflect the complex anatomical structure, tissue organisation, and functional capabilities found in living tissues in the body.

The intricate 3D configuration of organoids allows them to predict the effectiveness and safety of drugs during initial preclinical testing stages more accurately than simpler two-dimensional cell models. 

Organoid Research Models

Intestinal Organoids

Intestinal organoids accurately recapitulate many properties of the intestine, including cellular composition, histoarchitecture, and functionality.

 

Epistem's intestinal organoid system enables evaluation of multiple test compounds. Organoids are exposed to the test substances, and various endpoints can be measured after 7 days. Both visual scoring of morphology (viability and branching) and total viability using an ATP luminescence assay are conducted to quantify effects. Dose-response data are then used to determine the compound's IC50 or EC50 value. 

Organoid-Derived Monolayer Assays

The monolayers are cultured on permeable supports that permit separate access to the basal and apical sides of the epithelium, while retaining the differentiated cell types originating from the organoid.

 

This in vitro model offers an innovative approach to evaluate the toxic effects of systemically or orally administered drugs on the integrity of the small intestinal barrier. This platform can also be used to intentionally induce temporary disruption of tight junctions in order to improve the bioavailability of orally delivered medications through the intestinal epithelium.

REGISTER FOR THE WEBINAR
TODAY
DOWNLOAD THE BROCHURE
TODAY

© 2016, 2023 Epistem Ltd. Privacy policy | Terms of use